Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

haemophilia B

- PMLiVE

bluebird bio submits US application for sickle cell gene therapy

The genetic disease affects approximately 100,000 people in the US alone

- PMLiVE

AstraZeneca’s Lynparza recommended by NICE for breast and prostate cancer

An estimated 800 patients will now be eligible for treatment with the drug

- PMLiVE

NICE publishes draft guidance not recommending Ipsen’s Cabometyx for thyroid cancer

Up to 15% of patients with differentiated thyroid cancer do not respond to radioactive iodine

- PMLiVE

AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma

An estimated 98,000 patients with severe uncontrolled asthma may be eligible for the new treatment

- PMLiVE

MSD’s Keytruda to be made available in England for advanced cervical cancer patients

Around 2,600 people are diagnosed with cervical cancer each year in England

Can Cinderella save us?

NICE sees ‘promise’ in four UTI tests that could help in fight against AMR

The tests can identify the presence of bacteria in a urine sample in less than 40 minutes

- PMLiVE

Novo Nordisk’s weight-loss drug recommended by NICE

The drug, semaglutide, will be offered to eligible adults for a maximum of two years

EU flag

EC approves first gene therapy for adults with haemophilia B

Typically, haemophilia B patients must adhere to strict, lifelong IV infusion schedules

- PMLiVE

NICE publishes final draft guidance recommending three COVID-19 treatments

The medicines have shown promise in treating COVID-19 and been found cost-effective

- PMLiVE

Sanofi’s enzyme replacement therapy available on NHS to Pompe disease patients

The rare genetic disorder affects around one in every 40,000 people in the UK

- PMLiVE

Roche’s Polivy recommended by NICE for lymphoma therapy

Around 5,500 people in England are diagnosed with the aggressive blood cancer each year

- PMLiVE

Gilead’s CAR-T cell therapy recommended by NICE for lymphoma

Yescarta is the first CAR T-cell therapy recommended for routine use on the NHS

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links